EUVIMEDEUVIMED entdecken
Crossref

Molecular alteration profiles characterize intraductal carcinoma of the prostate

Harshitha Dudipala iD, Shayan S Nazari, Isabela Werneck da Cunha, Nathan Coligado, Yasmine Baca iD, Shuanzeng Wei, Andrew Elliott, Norm D Smith, Daniel M Geynisman, Jacqueline T Brown, Kevin K Zarrabi, Neeraj Agarwal und 3 weitere

Cancer · 2026

DOI: 10.1002/cncr.70238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Harshitha Dudipala und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Biomarkers, Tumor, Carcinoma, Ductal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intraductal carcinoma of the prostate (IDC‐P) is an intra‐acinar and/or intraductal neoplastic epithelial proliferation that is a distinct histological entity according to the 2016 World Health Organization (WHO) classification system. Clinically, it is associated with higher grade tumors and a more aggressive disease course. However, the molecular underpinnings of IDC‐P are not well elucidated.

Methods

This study identified radical prostatectomy (RP) cases from the Caris Life Sciences database, classified as prostatic adenocarcinoma with grade group 4/5 or with the words “cribriform,” “necrosis,” or “intraductal” in the pathology report. Digitized hematoxylin–eosin slides underwent central pathology review by a board‐certified genitourinary pathologist to identify the presence of IDC‐P according to the 2022 WHO classification. IDC‐P cases ( n = 175) were compared to non–IDC‐P cases ( n = 5334). Prostatic tumor specimens were sequenced via next‐generation DNA/RNA sequencing.

Results

Compared to non–IDC‐P cases, the IDC‐P cohort had significantly more mutations in MUTYH (4.5% vs. 1.4%; p < .01), FANCA (2.7% vs. 0.5%; p < .01), NBN (2.5% vs. 0.6%; p < .05), and MTOR (0.6% vs. 0.1%; p < .05). IDC‐P tumors were enriched for DLL3 and CEACAM5 expression, with lower expression of STEAP1, TROP2, ERBB2, PSCA, and B7‐H3, compared to non–IDC‐P tumors. IDC‐P had significantly higher neuroendocrine prostate cancer signature scores and IFN‐γ signature scores, and similar androgen receptor signature scores, compared to non–IDC‐P. The tumor microenvironment of IDC‐P had significantly higher cell fractions of M2 macrophages and fewer dendritic cells.

Conclusions

IDC‐P possesses a distinct molecular and immunological profile. Understanding these molecular underpinnings is crucial for the development of personalized treatment strategies for histologically distinct prostate cancer subsets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCarcinoma, Intraductal, NoninfiltratingBiomarkers, TumorCarcinoma, DuctalHumansMaleAgedMiddle AgedProstatectomyMutationTumor MicroenvironmentHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

immune profileintraductalmolecular alterationspersonalized treatmentprostate cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, California, USA.
  • Caris Life Sciences, Phoenix, Arizona, USA.
  • Oncologia D`Or, Instituto D`Or de Ensino e Pesquisa, Rio de Janeiro, Brazil.
  • Undergraduate Studies, University of California, San Diego, California, USA.
  • Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Division of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Harshitha Dudipala, Yasmine Baca

Zitieren

APA

Dudipala, H., Nazari, S. S., Werneck da Cunha, I., Coligado, N., Baca, Y., Wei, S., Elliott, A., Smith, N. D., Geynisman, D. M., Brown, J. T., Zarrabi, K. K., Agarwal, N., Antonarakis, E. S., Herchenhorn, D., & McKay, R. R. (2026). Molecular alteration profiles characterize intraductal carcinoma of the prostate. Cancer. https://doi.org/10.1002/cncr.70238

Vancouver

Dudipala H, Nazari SS, Werneck da Cunha I, Coligado N, Baca Y, Wei S, et al. Molecular alteration profiles characterize intraductal carcinoma of the prostate. Cancer. 2026. doi:10.1002/cncr.70238

BibTeX
@article{Dudipala2026,
  author = {Dudipala, Harshitha and Nazari, Shayan S and Werneck da Cunha, Isabela and Coligado, Nathan and Baca, Yasmine and Wei, Shuanzeng and Elliott, Andrew and Smith, Norm D and Geynisman, Daniel M and Brown, Jacqueline T and Zarrabi, Kevin K and Agarwal, Neeraj and Antonarakis, Emmanuel S and Herchenhorn, Daniel and McKay, Rana R},
  title = {Molecular alteration profiles characterize intraductal carcinoma of the prostate},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70238}
}
Kostenlos starten →